These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23630586)

  • 1. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
    Chaowanachan T; Krogstad E; Ball C; Woodrow KA
    PLoS One; 2013; 8(4):e61416. PubMed ID: 23630586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
    Feng JY; Ly JK; Myrick F; Goodman D; White KL; Svarovskaia ES; Borroto-Esoda K; Miller MD
    Retrovirology; 2009 May; 6():44. PubMed ID: 19439089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
    Date AA; Shibata A; Goede M; Sanford B; La Bruzzo K; Belshan M; Destache CJ
    Antiviral Res; 2012 Dec; 96(3):430-6. PubMed ID: 23041201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
    Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
    Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
    Minooei F; Fried JR; Fuqua JL; Palmer KE; Steinbach-Rankins JM
    Int J Nanomedicine; 2021; 16():1189-1206. PubMed ID: 33623382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.
    Destache CJ; Belgum T; Christensen K; Shibata A; Sharma A; Dash A
    BMC Infect Dis; 2009 Dec; 9():198. PubMed ID: 20003214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission.
    Zhang T; Sturgis TF; Youan BB
    Eur J Pharm Biopharm; 2011 Nov; 79(3):526-36. PubMed ID: 21736940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs.
    Cunha-Reis C; Machado A; Barreiros L; Araújo F; Nunes R; Seabra V; Ferreira D; Segundo MA; Sarmento B; das Neves J
    J Control Release; 2016 Dec; 243():43-53. PubMed ID: 27664327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.
    Bousquet L; Pruvost A; Guyot AC; Farinotti R; Mabondzo A
    Antimicrob Agents Chemother; 2009 Mar; 53(3):896-902. PubMed ID: 19075072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
    Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent findings on the mechanisms involved in tenofovir resistance.
    Iyidogan P; Anderson KS
    Antivir Chem Chemother; 2014 Dec; 23(6):217-22. PubMed ID: 23744599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application.
    Leporati A; Gupta S; Bolotin E; Castillo G; Alfaro J; Gottikh MB; Bogdanov AA
    Pharm Res; 2019 Mar; 36(5):73. PubMed ID: 30919089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.
    Dezzutti CS; Shetler C; Mahalingam A; Ugaonkar SR; Gwozdz G; Buckheit KW; Buckheit RW
    Antiviral Res; 2012 Nov; 96(2):221-5. PubMed ID: 22940075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
    Kulkarni R; Feng JY; Miller MD; White KL
    Antiviral Res; 2014 Jan; 101():131-5. PubMed ID: 24291780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.
    Shibata A; McMullen E; Pham A; Belshan M; Sanford B; Zhou Y; Goede M; Date AA; Destache CJ
    AIDS Res Hum Retroviruses; 2013 May; 29(5):746-54. PubMed ID: 23289671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
    Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
    Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.
    Date AA; Shibata A; McMullen E; La Bruzzo K; Bruck P; Belshan M; Zhou Y; Destache CJ
    J Biomed Nanotechnol; 2015 Mar; 11(3):416-27. PubMed ID: 26307825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention.
    Alukda D; Sturgis T; Youan BC
    J Pharm Sci; 2011 Aug; 100(8):3345-3356. PubMed ID: 21437910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity.
    Singh R; Kesharwani P; Mehra NK; Singh S; Banerjee S; Jain NK
    Drug Dev Ind Pharm; 2015; 41(11):1888-901. PubMed ID: 25738812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.